Research suggests progranulin and JAK2/STAT3 signaling enhance white blood cell maturation — Evidence Review

A new study from Iowa State University identifies progranulin and JAK2/STAT3 signaling as key factors enabling the maturation of leukemia cells, offering a potential new therapeutic strategy. Most related studies support the importance of these pathways in blood cell development and cancer, though their precise roles in leukemia progression remain debated.

• Multiple studies confirm that progranulin is highly expressed in aggressive leukemia and other cancers, and is associated with poor prognosis, but evidence is mixed on whether progranulin actively drives disease or mainly serves as a marker 2 3 5.
• JAK2/STAT3 signaling is widely recognized as a central pathway in cancer development and stem cell differentiation, with both oncogenic and immune regulatory functions; targeting this axis is a major focus of current cancer research 6 7 8 9 10.
• The new findings build on animal and in vitro studies showing that manipulating these factors can impact blood cell differentiation and proliferation, supporting the therapeutic potential of modulating these pathways in leukemia 4 5 13.

Study Overview and Key Findings

In aggressive leukemias, immature blood cells often become stuck in early development stages, leading to their abnormal accumulation and disruption of healthy blood cell production. The Iowa State University study sought to understand what molecular signals are missing in these cells and whether restoring them could promote their maturation and eventual death. By leveraging zebrafish as a model organism—due to their unique expression of progranulin in blood cells—the researchers identified a cooperative requirement for both progranulin and active JAK2/STAT3 signaling to drive the differentiation of myeloid progenitor cells into mature macrophages in both zebrafish and human leukemia cells. Importantly, this combination overcame the developmental blockade in leukemic cells that had previously resisted maturation, suggesting a new avenue for therapeutic intervention.

Property	Value
Study Year	2026
Organization	Iowa State University
Journal Name	Cell Reports
Authors	Abbigail McCune, Masuma Khatun Usha, Inga Baldus, C.J. Willett, Noemi Ferrito, Radwa Barakat, Emilee Clemensen, Elizabeth Snella, Mark Morton, Jesus Lacal, Giulia Pavani, Clyde A. Campbell, Raquel Espin-Palazon
Population	Human leukemia cells
Methods	Animal Study
Outcome	Differentiation of immature blood cells into functional white blood cells
Results	Progranulin and JAK2/STAT3 signaling led to maturation of leukemia cells.

Literature Review: Related Studies

To assess how this study fits within the wider scientific context, we searched the Consensus paper database, which covers over 200 million research papers. The following search queries were used to identify relevant literature:

1. progranulin leukemia cell maturation
2. JAK2 STAT3 signaling cancer treatment
3. white blood cell differentiation mechanisms

Summary Table of Related Studies

Topic	Key Findings
How does progranulin influence leukemia progression and prognosis?	- Progranulin is overexpressed in aggressive leukemias and is associated with poorer prognosis and shorter survival 2 3 5. - Some studies question whether progranulin actively drives disease or simply marks more aggressive leukemia; functional roles in proliferation and differentiation are still being clarified 3 4.
What is the role of JAK2/STAT3 signaling in cancer and immune regulation?	- JAK2/STAT3 signaling is a central pathway in cancer cell survival, proliferation, and immune escape; persistent activation drives oncogenesis in various cancers 6 7 8 9 10. - Targeting JAK2/STAT3 is a major focus for new therapies, but the pathway has complex, context-dependent effects, including in hematopoietic cells 8 9 10.
What molecular mechanisms govern white blood cell differentiation?	- Differentiation of myeloid progenitors into mature cells is tightly regulated by feedback signals, cytokines, and genetic factors; disruptions can cause disease 11 13 14 15. - Mathematical and experimental models show both discrete and continuous differentiation processes, with feedback and signaling pathways controlling fate decisions 13 14 15.
Can manipulating differentiation signals serve as a therapeutic strategy?	- Inducing differentiation in hematopoietic cancers (e.g., by targeting progranulin or signaling pathways) can inhibit proliferation or drive malignant cells toward cell death, though success varies by context 4 5. - Animal and in vitro models support the feasibility of targeting differentiation machinery for therapy 4 5 13.

---

How does progranulin influence leukemia progression and prognosis?

Research consistently finds that progranulin is elevated in aggressive forms of leukemia and is correlated with worse clinical outcomes, such as shorter relapse-free and overall survival 2 3 5. However, recent studies raise questions about whether progranulin directly drives leukemic cell proliferation or is primarily a marker of disease aggressiveness. The new Iowa State University study adds functional evidence that progranulin, in concert with JAK2/STAT3 signaling, can actively promote the differentiation and maturation of leukemia cells—a finding that refines our understanding of its role.

• High progranulin expression is linked to poor prognosis and increased risk of disease progression in both chronic lymphocytic and acute myeloid leukemia 2 5.
• Some studies found no direct effect of recombinant progranulin on leukemia cell viability, suggesting its role as a biomarker rather than a driver 3.
• Manipulating progranulin levels alters proliferation and differentiation in hematopoietic cancer cell lines, indicating a potential therapeutic target 4.
• The current study demonstrates a functional requirement for progranulin in overcoming leukemic cell maturation blocks, expanding its role beyond that of a prognostic marker 4 5.

What is the role of JAK2/STAT3 signaling in cancer and immune regulation?

JAK2/STAT3 signaling is widely recognized as a critical pathway for cancer cell survival, proliferation, and immune system modulation 6 7 8 9 10. Persistent activation of this pathway can drive oncogenesis, while targeted inhibition is being investigated as a therapeutic strategy in both solid and hematological malignancies. However, the pathway’s effects are highly context-dependent, with roles in both promoting and restraining tumor growth depending on cell type and microenvironment.

• The JAK2/STAT3 axis is central to cellular transformation, cancer stemness, and resistance to therapy in diverse cancers 6 7 8 10.
• Inhibitors targeting JAK2 or STAT3 show promise in preclinical cancer models, but off-target and immune-modulatory effects remain challenges 6 8 9.
• The pathway also mediates essential immune functions, complicating efforts to selectively target its oncogenic activities 8 9.
• The new study’s finding that active JAK2/STAT3 signaling is required (alongside progranulin) for leukemia cell maturation highlights a potentially exploitable vulnerability in developmentally arrested leukemias 10.

What molecular mechanisms govern white blood cell differentiation?

White blood cell differentiation from hematopoietic stem and progenitor cells is orchestrated by a complex network of cytokines, transcription factors, and feedback signals 11 13 14 15. Disruptions in these processes underlie many blood disorders, including leukemia. Mathematical and experimental models help clarify how different pathways and molecular signals guide cell fate decisions.

• Genetic studies identify numerous loci and signaling pathways (including JAK2/STAT3) that regulate myeloid and lymphoid differentiation and are shared with autoimmune disease risk 11.
• Cytokine signaling, especially via colony-stimulating factors, is a major driver of progenitor cell fate 13.
• Models suggest both discrete stage-wise and continuous maturation processes, with feedback mechanisms maintaining homeostasis 14 15.
• The current study adds progranulin and JAK2/STAT3 as necessary components for transition from progenitor to mature myeloid cells in leukemia, contributing to this molecular map 13 14 15.

Can manipulating differentiation signals serve as a therapeutic strategy?

Efforts to treat leukemia by forcing malignant cells to mature—effectively removing their proliferative capacity—have a long history, including the established use of differentiation agents in certain leukemias. Recent work, including the current study, supports the idea that targeting molecules like progranulin or key signaling pathways can overcome developmental blocks in other leukemia subtypes 4 5 13.

• Progranulin depletion or addition of differentiation-inducing signals can reduce proliferation and promote maturation in some hematopoietic cancer models 4 5.
• Therapeutic manipulation of differentiation pathways is supported by both animal and in vitro data, though translating these findings to clinical treatments remains challenging 4 5 13.
• The specific requirement for both progranulin and JAK2/STAT3 activity, as identified in the Iowa State study, suggests a more nuanced approach may be needed for effective therapy 4 5.
• Recognizing and producing distinct macrophage lineages with regenerative properties may open further avenues for tissue repair and cancer therapy 13.

Future Research Questions

While this study advances understanding of the molecular mechanisms controlling leukemia cell differentiation, several important questions remain. Further research is needed to clarify the safety and efficacy of manipulating these pathways in humans, the specificity of these signals for different leukemia subtypes, and how these findings can be translated into practical therapies.

Research Question	Relevance
Does combining progranulin and JAK2/STAT3 activation promote maturation in all types of leukemia cells?	It is unknown whether the observed effect is limited to specific leukemia subtypes or is a generalizable mechanism across different forms of leukemia 5 10.
What are the potential side effects of stimulating JAK2/STAT3 signaling in human patients?	JAK2/STAT3 signaling is involved in multiple physiological and pathological processes, so unintended immune or oncogenic consequences could arise from therapeutic activation 8 9.
Can therapeutic production of specific macrophage lineages improve tissue regeneration and cancer outcomes?	The study identifies distinct macrophage types with different regenerative capacities, suggesting that producing the right cell type may be critical for therapy 13.
How does progranulin interact with other signaling pathways in leukemia cell differentiation?	Progranulin is known to interact with multiple signaling cascades (e.g., TGF-β, Akt/mTOR), and understanding these cross-talks could help refine therapeutic approaches 1 4.
Is high progranulin expression a driver of leukemia progression, or primarily a biomarker?	Existing studies disagree on whether progranulin is causative in leukemia or simply reflects disease severity; clarifying this distinction is vital for targeting it therapeutically 2 3 4.